Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of etanercept using logistic regression analysis.

被引：0
|
作者：
Lee, H
Kimko, HC
Rogge, M
Wang, D
Nestorov, I
Peck, CC
机构：
[1] Georgetown Univ, Ctr Drug Dev Sci, Washington, DC 20057 USA
[2] Immunex Corp, Washington, DC USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P84 / P84
页数：1
相关论文
共 50 条
  • [1] Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
    Lee, H
    Kimko, HC
    Rogge, M
    Wang, D
    Nestorov, I
    Peck, CC
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) : 348 - 365
  • [2] COMBINED PHARMACOKINETIC PHARMACODYNAMIC (PK/PD) MODELING
    COLBURN, WA
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (09): : 769 - 771
  • [3] Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb
    Bender, B.
    Xiang, H.
    Reyes, A. E., II
    Damico, L. A.
    Merchant, M.
    Peterson, A.
    Forrest, W.
    Jumbe, N. L.
    [J]. EJC SUPPLEMENTS, 2008, 6 (12): : 170 - 170
  • [4] A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients
    Mould, D
    Chapelsky, M
    Aluri, J
    Swagzdis, A
    Samuels, R
    Granett, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) : 210 - 222
  • [5] Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of etanercept in patients with juvenile rheumatoid arthritis (JRA) using a dichotomous clinical endpoint.
    Yim, D
    Zhou, H
    Peck, CC
    Lee, H
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P92 - P92
  • [6] Impact of population pharmacokinetic (PK) modeling, logistic regression and PK/pharmacodynamic (PD) simulation of solabeoron to aid in the dose selection of a phase IIB study in patients with irritable dowel syndrome (IBS).
    Cox, Donna S.
    Boyle, Duane A.
    Foss, Michael J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1101 - 1101
  • [7] Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives
    Hartmut Derendorf
    Bernd Meibohm
    [J]. Pharmaceutical Research, 1999, 16 : 176 - 185
  • [8] Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives
    Derendorf, H
    Meibohm, B
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 176 - 185
  • [9] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DEPOT TESTOSTERONE CYPIONATE IN HEALTHY MALE SUBJECTS
    Bi, Y.
    Murry, D.
    Ellerby, M.
    Perry, P. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S80 - S81
  • [10] POPULATION PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) MODELING OF TICARCILLIN-CLAVULANATE IN PEDIATRIC CF PATIENTS
    Zobell, J. T.
    Stockmann, C.
    Young, D. C.
    Cash, J.
    Sherwin, C.
    Spigarelli, M.
    Chatfield, B. A.
    Ampofo, K.
    [J]. PEDIATRIC PULMONOLOGY, 2011, : 311 - 312
12345